Welcome NeuvaRx to the OBI!
NeuvaRx is preclinical-stage biopharmaceutical company dedicated to the development of therapies and diagnostic tools for neurovascular disorders, including, but not limited to ischemic and hemorrhagic stroke and vascular dementia.
We are happy to have you onboard!
OBI Client Company Wins
- Participated in the Research in Your Back Yard panel at the OBI in May.
- Recently enrolled a third patient in their clinical trial at Fred Hutchinson Cancer Center in Seattle and will soon be opening a second trial site at Providence Cancer Center, Portland.
- StoneStable founder and CSO Ken Stedman received the 2022 ARIS Impact Goals Award! Read press release for details.
- StoneStable, Inc. was one of the finalists for the Angel Oregon Life & Bio (AOBIO) investment!
- We filed a Provisional Patent Application in United States No. 63/268,605: “Use of γ’ fibrinogen as a Biomarker in the Detection of Covid-19 and Prognosis of Severe Disease.”
- And we filed a pre-Emergency Use Authorization to the FDA entitled: “Gamma-prime fibrinogen ELISA.”
- Hemex Health announced a significant enhancement to their Gazelle™ Hb Variant test, which allows for more precise measurements of Hb F, also known as fetal hemoglobin. The increased accuracy could be useful for monitoring hydroxyurea therapy in point-of-care settings. Hemex will provide “over the air” updates with the Hb F enhancement that can be downloaded directly to existing Gazelle Readers. The improvement will ship with new systems. Read press release here.
- The most recent episode (Season 4 – Episode 3 entitled “A Smell from Hell”) of “My Feet are Killing Me” featured HEMIGARD being used by “Dr. Brad” to close a very tough plantar wound. It does have graphic content including live surgery footage. The patient in question can hardly walk due to masses of callus on the ball of her foot – the surgical excision leaves a large wound that is difficult to close, and Dr. Brad uses HEMIGARD to help close the defect. The patient has an excellent result and is ecstatic! View it on Amazon Prime or other streaming platforms.
- Congratulations to Inherent Targeting, one of the finalists for Angel Oregon Life & Bio (AOBIO).
Sparrow Pharmaceuticals (an OBI alumnus)
- Sparrow Pharmaceuticals received ethics committee and regulatory authority go-ahead for three Phase 2 clinical trials, in patients with Cushing syndrome, autonomous cortisol secretion, and polymyalgia rheumatica.
- Dr. David Katz was selected to give oral presentations on new clinical pharmacology and non-clinical study results at three prestigious conferences in May-June: European Congress of Endocrinology in Milan, European League Against Rheumatism in Copenhagen, and Endocrine Society in Atlanta. Read press release here.
AOBIO Congratulations!
A fabulous afternoon at the inaugural Angel Oregon Life & Bioscience (AOBIO) Grand Finale & Innovation Showcase, an in-person celebration on May 26th, 2022, 3-7 p.m. at Amaterra Winery in Portland.
OBI & OTRADI Executive Director Heather Ellis (pictured below, left) and Amanda Oborne from OEN (right) presented the Big Check to Ray Browning, co-founder of Biomotum, winner of the ~$300,000 AOBIO Investors’ angel investment!
Congratulations to all of the 2022 AOBIO finalists: Inherent Targeting, Savorease Therapeutic Foods, and StoneStable!
Also big congratulations to High Peak Medical Systems, who won the EMERGE award, sponsored by Black Founders Matter Fund.
AOBIO is a collaborative effort by Oregon Entrepreneurs Network, OHSU, Oregon Bioscience Association, and OBI/OTRADI. Thanks to everyone who participated in making this program a success!
OBI Mentor of the Month:
Shelly Sweeney
Shelly Sweeney is the Founder and Solopreneur Business Coach of Beeline Coaching. She joined the OBI Mentoring Program in January, 2022 and receives high praise from her mentee each month. Her past experience with startups include working with entrepreneurs and startups, as well as surgical device startups.
Shelly says, “I have always been a leader out-performing goals wherever I have worked and someone managers described as someone they wish ‘they had nine more of.’ My coworkers describe me as someone who they can call to listen to them, share ideas and be a positive influence.” We agree! Thank you, Shelly, for all you do for the OBI community!
Hiring or Seeking?
Post it on OBI’s Job Board!
OBI has launched a Job Board where you can easily list your organization’s open positions. Click here to post your open positions. We’ll approve it on our end, and it will be posted for 30 days (and it’s renewable too).
And, if you’re a job seeker and would like to have your resume reviewed by recruiters in the community, please upload your resume to the “submit resume” section of our job board.
OBI’s New Shared Lab
Sponsored by PhRMA
On May 20, to celebrate International Clinical Trials Day, we held a Research in Your Back Yard panel discussion program, followed by a ribbon cutting for our newest shared equipment lab for OBI client companies. Thanks to a generous donation by PhRMA, we outfitted our new shared lab with a biosafety cabinet, CO2 incubators, centrifuge, rocker platform, and vortex mixer.
Thank you to PhRMA for your support!
OBI Clients Earn Share of NIH Grants in Oregon
OBI & OTRADI current and graduated client companies made up eight of the 44 largest NIH grant recipients in Oregon for fiscal year 2021! Published in the Portland Business Journal in April, 2022, we were well-represented with the following rankings:
PDX Pharmaceuticals #9, Aronora #11, Hemex Health #14, Virogenomics BioDevelopment #18, Rewire Neuro #20, Madorra #23, Veana Therapeutics #29, and Inherent Targeting #39.
Rankings were determined by NIH grant dollar amounts in FY 2021; data was provided by the Department of Health & Human Services. Congratulations! We can’t wait to see what 2022 brings!
Brand New Office & Lab Space Available
Looking for office and/or wet lab space for your bioscience, medical device, or health innovation startup? Would you like to become a part of the OBI startup community? We are nearing completion on brand new office and lab space in our Willamette Wharf building. Learn more here by filling out a facilities request form, and let’s talk.
Upcoming Events
Zapproved & Cinder:
Voices of Equity
Gender Identity & Pronouns
One Non-Binary Story
June 10, 2022
9:00-9:30 AM
Register here
OBI Hybrid Lunch & Learn
Women in Leadership Part 2:
Continuing the Conversation
June 22, 2022
12:00-1:00 PM
Register here
Oregon Bioscience Association:
OBW CONNECT Live
with Emily Leproust of Twist Bioscience
July 7, 2022
5:00-8:00 PM
Tickets here
Save the Date!
OBI Accelerate Biotech + Digital Health
July Happy Hour
July 14, 2022
5:30-7:00 PM
Canvas Rooftop
Save the Date